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Objective. To uniquely classify children with micro-
scopic polyangiitis (MPA), to describe their demographic
characteristics, presenting clinical features, and initial
treatments in comparison to patients with granulomatosis
with polyangiitis (Wegener’s) (GPA).
Methods. The European Medicines Agency (EMA)
classification algorithm was applied by computation to
categorical data from patients recruited to the ARChiVe
(A Registry for Childhood Vasculitis: e-entry) cohort, with
the data censored to November 2015. The EMA algorithm
was used to uniquely distinguish children with MPA from
children with GPA, whose diagnoses had been classified
according to both adult- and pediatric-specific criteria.
Descriptive statistics were used for comparisons.
Results. In total, 231 of 440 patients (64% female)
fulfilled the classification criteria for either MPA (n5 48)
or GPA (n5 183). The median time to diagnosis was 1.6
months in the MPA group and 2.1 months in the GPA
group (ranging to 39 and 73 months, respectively).
Patients with MPA were significantly younger than those
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with GPA (median age 11 years versus 14 years).
Constitutional features were equally common between the
groups. In patients with MPA compared to those with
GPA, pulmonary manifestations were less frequent (44%
versus 74%) and less severe (primarily, hemorrhage,
requirement for supplemental oxygen, and pulmonary fail-
ure). Renal pathologic features were frequently found in
both groups (75% of patients with MPA versus 83% of
patients with GPA) but tended toward greater severity in
those with MPA (primarily, nephrotic-range proteinuria,
requirement for dialysis, and end-stage renal disease).
Airway/eye involvement was absent among patients with
MPA, because these GPA-defining features preclude a
diagnosis of MPA within the EMA algorithm. Similar pro-
portions of patients with MPA and those with GPA
received combination therapy with corticosteroids plus
cyclophosphamide (69% and 78%, respectively) or both
drugs in combination with plasmapheresis (19% and 22%,
respectively). Other treatments administered, ranging in
decreasing frequency from 13% to 3%, were rituximab,
methotrexate, azathioprine, andmycophenolatemofetil.
Conclusion. Younger age at disease onset and,
perhaps, both gastrointestinal manifestations and more
severe kidney disease seem to characterize the clinical
profile in children with MPA compared to those with
GPA. Delay in diagnosis suggests that recognition of
these systemic vasculitides is suboptimal. Compared
with adults, initial treatment regimens in children were
comparable, but the complete reversal of female-to-male
disease prevalence ratios is a provocative finding.
Microscopic polyangiitis (MPA) and granulomatosis
with polyangiitis (Wegener’s) (GPA) are primary systemic
vasculitides that predominantly affect small blood vessels,
and are collectively grouped under the umbrella term of
antineutrophil cytoplasmic antibody (ANCA)–associated
vasculitis (AAV) (1,2). The limited literature available
suggests that genetic, pathophysiologic, and prognostic dif-
ferences exist between MPA and GPA, and this may be rele-
vant to continuing biologic discovery and targeted therapy
(3). Distinguishing between these diseases is challenging,
because their clinical features are overlapping, standardized
definitions are lacking, and mutually exclusive classification
criteria have yet to be established. In the pediatric popula-
tion especially, in whom there are only a few reported cases,
accurate assessment of disease-specific epidemiologic data,
prognostic implications, and biologic discovery has been
particularly limited.
The American College of Rheumatology (ACR)
has the most commonly used system for classifying vasculi-
tis (referred to as the ACR 1990 Criteria for Vasculitis)
(4). However, a pediatric adaptation of these ACR criteria,
the European League Against Rheumatism/Paediatric
Rheumatology International Trials Organisation/Pediatric
Rheumatology European Society (EULAR/PRINTO/PRES)
2008 criteria, is reported to have improved specificity
and sensitivity for the classification of childhood GPA
(5–7). Neither the pediatric disease classification system
nor the adult disease classification system has categorical
criteria for MPA, and as a result, many patients defined
as having MPA might also be concurrently classified as
having GPA or polyarteritis nodosa (PAN), depending
on how the disease definitions, such as those proposed
by the Chapel Hill Consensus Conference (CHCC), are
interpreted by individual physicians (2,6,8,9). Many clini-
cal studies and trials have avoided this conundrum by
considering GPA and MPA collectively. On the other
hand, Watts et al proposed a classification algorithm,
which was developed by consensus and subsequently
adopted by the European Medicines Agency (EMA),
that can classify patients with all types of AAV and PAN
into mutually exclusive diagnostic categories (10).
Specifically, the EMA algorithm has been adopted as a
practical tool for clinical trials and clinical studies of
AAV in adult patients (11,12), and was also applied in a
previous study by our group, in which pediatric patients
with GPA were actively distinguished from those with
MPA using this algorithm (6). However, the EMA algo-
rithm has not been adopted for routine clinical practice.
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The multicenter, contemporary inception cohort
known as ARChiVe (A Registry for Childhood Vasculitis:
e-entry) has previously reported the largest cohort of
children with GPA studied to date (5). Conversely, de-
scriptions of childhood MPA remain limited to only a few
studies, in which fewer than 26 patients have been
assessed and in which the included patients have not
always been uniquely classified (13–17).
In the present study, we aimed to describe the
presenting features of childhood MPA among the
subcohort of AAV patients recruited to ARChiVe who
were uniquely classified as having MPA; that is, after
application of the EMA algorithm, these children were
found to have no features that would be considered surro-
gate markers of GPA. We also aimed to compare these
patients classified as having MPA against a larger accu-
mulated subcohort of patients formally classified as hav-
ing GPA by either the ACR 1990 Criteria for Vasculitis
or the EULAR/PRINTO/PRES 2008 classification crite-
ria, with the goal of identifying variations in clinical phe-
notype, diagnostic evaluations, and treatment.
PATIENTS AND METHODS
ARChiVe was first launched in March 2007, and at the
time of censoring for this study, 45 pediatric rheumatologists at
45 geographically diverse institutions in Canada (n5 6), the US
(n5 34), Europe (n5 3), and Asia (n5 2) had contributed
patients. Patient eligibility criteria, the Registry data set, and the
strategy for establishing the time to diagnosis have been described
previously (5). Briefly, eligible patients included those who were
diagnosed as having a primary chronic systemic vasculitis by the
treating physician (i.e., given an MD diagnosis) after January 1,
2004 and before the age of 18 years. Patient data were collected
retrospectively for those diagnosed before March 2007, and pro-
spectively for those diagnosed subsequently, up to November
2015. Specific patient data items for categorical capture included
all criteria that are required for formal diagnosis using either the
ACR 1990 Criteria for Vasculitis (4) or the EULAR/PRINTO/
PRES classification system (7). In addition, other categorical
information, which has been described in the CHCC disease defi-
nitions (2,8) and is incorporated in the EMA algorithm for classi-
fying AAV subtypes and PAN (6), was included. The diagnosis in
patients could then be formally reclassified according to any of
these criteria, by computation of the data.
The specific experience of individual physicians in
diagnosing and caring for children with chronic vasculitis is
limited, as was recognized in a 2005 survey in which the median
number of patients with an AAV diagnosed by any rheumatol-
ogist in a single year was,1 (18). A recent international survey
of 209 pediatric rheumatologists (Cabral DA, et al: unpub-
lished observations) supports these earlier findings, with
respondents showing no uniformity in their approach to the
subclassification of patients with AAV as having either GPA or
MPA. Individuals were classified according to either a single
criteria set or varied combinations of criteria, and as a result,
42% met the ACR 1990 Criteria for Vasculitis, 81% met the
EULAR/PRINTO/PRES classification criteria, 82% were clas-
sified according to a status of seropositivity for proteinase 3–
classic ANCAs (PR3-cANCA) (versus myeloperoxidase–peri-
nuclear ANCAs [MPO-pANCA]), 46% met the CHCC disease
definitions, and 27% met other informal criteria. One-third of
respondents reported that their final diagnosis was often AAV.
Thus, not all patients were routinely subclassified as having a
diagnosis of either GPA or MPA.
Therefore, for the present study, in which we sought to
distinguish children with MPA from those with GPA, we did not
use physician diagnoses or physician classifications, since there
are no standardized diagnostic criteria and there was no uniform
approach among the physicians from the 45 contributing sites,
whose experience with AAVs varies. To systematically ensure uni-
formity, all patients with complete data who were enrolled in
ARChiVe up to November 2015 were selected to be uniformly
reclassified if they had the following submitting physician’s diag-
noses: GPA, limited GPA, MPA, ANCA-positive pauci-immune
glomerulonephritis, eosinophilic granulomatosis with polyangiitis
(Churg-Strauss) (EGPA), PAN, or unclassified small vessel or
medium vessel vasculitis. Selected patients were reclassified by
computation of categorical variables as follows. Patients consid-
ered as having GPA were classified according to the ACR 1990
Criteria for Vasculitis or the EULAR/PRINTO/PRES 2008 clas-
sification criteria, which also allowed comparison against similarly
defined cohorts of patients with GPA in other studies of pediatric
and adult subjects. Patients considered as having MPA were clas-
sified according to the EMA algorithm.
As described previously (6,10), the EMA algorithm
applies, in a sequential, stepwise manner, different classification
criteria, disease definitions, and disease-specific surrogate mark-
ers from the CHCC to distinguish patients with individual AAV
subtypes and PAN (Figure 1). Beginning with the most specific
criteria, the algorithm initially determines whether a diagnosis of
EGPA can be ruled out, using either the ACR criteria for EGPA
or the Lanham criteria (19,20). Thereafter, the EMA algorithm
determines whether a patient has GPA according to the ACR
1990 Criteria for Vasculitis or the EULAR/PRINTO/PRES 2008
classification criteria (using a pediatric modification of the algo-
rithm). These patients classified as having GPA were included in
the present study.
In the next step, the EMA algorithm assigns the classifi-
cation of GPA to additional patients using the CHCC definitions,
clinical surrogate features of GPA, and presence or absence of
ANCAs. We arbitrarily chose to exclude this group of patients
from the present study, describing them as having unclassifiable
AAV, because such patients were not included in the cohorts of
GPA patients in other comparator groups referred to herein.
Subsequently, the EMA algorithm determines whether a
patient has MPA according to the presence of defining histologic
features (CHCC definitions), clinical surrogates for renal vasculi-
tis, and ANCAs. Patients determined to have no overlapping
features of GPA are classified as having MPA, and these patients
were included in the present study. In the final step of the EMA
algorithm, patients are evaluated to determine whether they ful-
fill the CHCC definition of PAN, and these patients were
excluded from the present study.
Basic demographic characteristics, clinical features,
diagnostic data, and information on treatment usage at base-
line were primarily extracted for patients who were uniquely
classified as having either MPA or GPA.
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Study data were collected and managed using REDCap
electronic data capture tools hosted at the University of British
Columbia (21). Written informed consent was obtained from
each participant, and the study protocol was approved by the
ethics committee at each participating hospital (see Appendix A
for institutions and members of the ARChiVe Investigators
Network).
Descriptive statistics were generated using Stata (ver-
sion 13.1; StataCorp). Comparisons were made using chi-square
or Fisher’s exact tests for categorical variables, and Student’s
t-tests or Mann-Whitney U tests for continuous variables.
RESULTS
Classification. During the study period, among
the 440 children enrolled in the ARChiVe cohort, 374
patients with an initial clinical diagnosis (MD diagnosis) of
GPA or limited GPA (n5 224), MPA (n5 48), ANCA-
positive pauci-immune glomerulonephritis (n5 16), PAN
(n5 40), EGPA (n5 10), or unclassified small vessel vascu-
litis (n5 36) were selected for formal diagnostic reclassifi-
cation by computation of the data. A total of 231 patients
fulfilled the criteria for either MPA (n5 48) or GPA
(n5 183) and were included in the present study (Table 1).
Patients designated as having unclassifiable AAV (n5 62)
or those with PAN or other unclassifiable vasculitis (n5 71)
were excluded. Sixty-five of the 183 patients with GPA have
been described previously (21). No patients could be con-
currently classified as having both MPA and GPA.
Demographics. Collectively, patients with either
GPA or MPA were primarily white (55%) and female
(64%), and 90% (208 patients) were ANCA positive.
Children with MPA were significantly younger at the time
of disease onset than those with GPA (median difference
in age 3 years; P5 0.004). The interval between symptom
Figure 1. Formal classification of granulomatosis with polyangiitis
(Wegener’s) (GPA) and microscopic polyangiitis (MPA) assigned among an
ARChiVe (A Registry for Childhood Vasculitis: e-entry) cohort of 374
children with a physician’s (clinical MD) diagnosis of antineutrophil cytoplas-
mic antibody (ANCA)–associated vasculitis (AAV), polyarteritis nodosa
(PAN), or unclassified small vessel or medium vessel vasculitis. Classification
of GPA was performed according to either the American College of
Rheumatology (ACR) 1990 Criteria for Vasculitis or the European
League Against Rheumatism/Paediatric Rheumatology International Trials
Organisation/Pediatric Rheumatology European Society (EULAR/
PRINTO/PRES) 2008 classification criteria. Classification of MPA was
done according to the European Medicines Agency (EMA) classifica-
tion algorithm for classifying AAV and PAN. EGPA5 eosinophilic
granulomatosis with polyangiitis (Churg-Strauss); CHCC5Chapel
Hill Consensus Conference; PR35 proteinase 3; MPO5myeloperoxi-
dase; ELISA5 enzyme-linked immunosorbent assay.
Table 1. Characteristics of the ARChiVe study participants classified
as having MPA or GPA*
Characteristic
Patients
with MPA
(n5 48)
Patients
with GPA
(n5 183)
Female, no. (%) 35 (73) 113 (62)
Ethnicity, no. (%)
Asian 1 (2) 5 (3)
Black 0 (0) 4 (2)
Hispanic 6 (13)† 6 (3)
White 20 (42)† 107 (59)
Other/unknown 21 (44) 61 (33)
Age at diagnosis, years
Mean6 SD 11.26 4.5‡ 13.46 3.2
Median (range) 12 (1–18)‡ 14 (2–18)
Age at onset, years
Mean6 SD 10.86 4.7‡ 12.96 3.3
Median (range) 11 (1–18)‡ 14 (2–18)
Time to diagnosis, months
Mean6 SD 5.66 9.6 5.56 10.6
Median (range) 1.6 (0–39) 2.1 (0–73)
Physician diagnosis
(preclassification), no. (%)
MPA or isolated MPA 16 (33) 20 (11)
GPA or limited GPA 10 (21) 153 (84)
ANCA-positive
pauci-immune GN
7 (15) 2 (1)
PAN 6 (13) 0 (0)
Not classified 9 (19) 8 (4)
* ARChiVe5A Registry for Childhood Vasculitis: e-entry; MPA5
microscopic polyangiitis; ANCA5 antineutrophil cytoplasmic anti-
body; GN5 glomerulonephritis; PAN5 polyarteritis nodosa.
† P, 0.05 versus patients with granulomatosis with polyangiitis
(Wegener’s) (GPA).
‡ P, 0.01 versus patients with GPA.
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onset and diagnosis (time to diagnosis) varied widely both
between and within groups. For patients with MPA, the
median time to diagnosis was 1.6 months, while for GPA
patients, the median time to diagnosis was 2.1 months.
Demographic characteristics, the interval of time to diagno-
sis, and the initial MD diagnosis (prior to formal reclassifi-
cation) are presented in Table 1.
Presenting clinical features. Overview of system
involvement. Among patients with MPA, the systems
involved in a majority of patients, in order of decreasing fre-
quency, were constitutional (85%), renal (75%), gastroin-
testinal (58%), musculoskeletal (52%), and cutaneous
(52%). Among patients with GPA, the systems involved in
a majority of patients were constitutional (88%), renal
(83%), pulmonary (74%), upper airways/ear, nose, and
throat (ENT) (70%), and musculoskeletal (65%). The dif-
ference in the frequency of pulmonary involvement in
patients with GPA (74%) compared to patients with MPA
(44%) was statistically significant (P, 0.0001). The differ-
ence in frequency of upper airway involvement between
the 2 groups is not surprising, since, in the EMA algorithm,
specific ENT characteristics (as described below) are con-
sidered surrogate markers of GPA. Their presence in
patients who otherwise do not completely fulfill the classifi-
cation criteria for GPA precludes a unique diagnosis of
MPA (Figure 1). In our study, such patients are designated
as having unclassifiable AAV. The frequencies of specific
clinical features in the cohort with unclassifiable AAV are
summarized in Table 2 (together with the GPA and MPA
cohorts). Details on other basic characteristics are available
upon request from the corresponding author. Individual
organ–specific clinical features, laboratory and imaging
findings, and histopathologic features in the 2 cohorts with
GPA or MPA are described below and summarized in
Table 2.
Renal. The frequency and types of renal involve-
ment were similar between patients with MPA and
patients with GPA. Both cohorts exhibited common man-
ifestations of proteinuria, microscopic hematuria, and/or
red blood cell casts, an abnormal protein-to-creatinine
ratio, and impaired creatinine clearance. The serum cre-
atinine level was more often moderately to severely ele-
vated (.30% of the age-adjusted upper limit of normal)
among patients with MPA (48% versus 34% of patients
with GPA; P5 0.06), but this was not a statistically signif-
icant difference. Rates of nephrotic-range proteinuria,
renal failure requiring dialysis, or end-stage renal disease
were similarly low between the 2 groups, but all 3 renal
features tended to be more frequent among patients with
MPA than among those with GPA.
Renal biopsy samples were obtained from 32
patients with MPA and 108 patients with GPA. Among
these patients, histopathologic findings were consistent
with a diagnosis of pauci-immune and/or necrotizing glo-
merulonephritis in 30 (94%) of the patients with MPA
and 101 (94%) of the patients with GPA. Furthermore,
the findings on renal biopsy were consistent with a diagno-
sis of vasculitis in 24 patients with MPA (75%) and 74
patients with GPA (69%).
Pulmonary. Pulmonary involvement was overall
more frequent among patients with GPA compared to
patients with MPA, and individual symptomatic features,
such as chronic cough, alveolar hemorrhage, and massive
hemoptysis, were also significantly more frequent among
patients with GPA. Other pulmonary features, such as a
requirement for supplemental oxygen and respiratory
failure, also tended to be more frequent among patients
with GPA, but this was not statistically significantly dif-
ferent from that in patients with MPA.
Pulmonary imaging was performed in 92% of
patients with GPA and 81% of patients with MPA.
Results of the imaging revealed pulmonary abnormalities
in 89% of patients with GPA and 39% of patients with
MPA. The presence of nodules, fixed pulmonary
infiltrates, and/or cavitations, described as surrogate
features of GPA in the EMA algorithm (see Figure 1),
excluded a diagnosis of MPA, and therefore these 3
features were found only in the patients with GPA, at fre-
quencies of 54%, 36%, and 21%, respectively (Table 2).
Of note, among the 62 patients considered to have unclas-
sifiable AAV, only 5 patients (8%) had at least 1 of these
3 surrogate pulmonary imaging findings (Table 2). Pleural
effusions were found both in patients with MPA (10%)
and in patients with GPA (16%), and other findings, such
as fibrosis, septal thickening, and pneumothoraces, were
identified in fewer than 10% of images from either group.
Of the 31 patients with GPA in whom a lung biopsy
was performed, 24 (77%) had biopsy findings that con-
firmed the presence of vasculitis (48%) or that were consis-
tent with features of vasculitis (29%). Granulomatous
inflammation was identified in 4 patients, and 7 had no evi-
dence of vasculitis. In the 3 (and only) patients with MPA
who underwent lung biopsy, the histopathologic findings
confirmed the presence of vasculitis in 2 of the patients, and
the findings were consistent with features of vasculitis in 1
patient. No granulomas were seen in any biopsy sample.
Upper airways. Upper airway disease was a pre-
dominant presenting clinical feature among patients with
GPA (70%). The virtual absence of upper airway features
among patients with MPA is not surprising. Specifically,
having any nasal/sinus involvement or tracheal/subglottic
stenosis qualifies a patient as having 1 of the specific
EULAR/PRINTO/PRES criteria for the classification of
GPA (presence of 3 of 6 criteria required) (7). If patients
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Table 2. Presenting clinical features of the ARChiVe study participants classified as having MPA,
GPA, or unclassified AAV*
Clinical feature
Patients
with MPA
(n5 48)
Patients
with GPA
(n5 183)
Patients with
unclassifiable AAV
(n5 62)
Constitutional/general 41 (85) 160 (88) 39 (63)
Malaise, fatigue 37 (77) 152 (83) 33 (53)
Fever 25 (52) 97 (53) 22 (35)
Weight loss 15 (31) 80 (44) 10 (16)
Renal 36 (75) 151 (83) 24 (39)
Hypertension (age-adjusted) 16 (33) 39 (21) 8 (13)
Clinically “nephrotic” with edema 11 (23)† 20 (11) 2 (3)
Renal failure requiring dialysis 12 (25)† 24 (13) 4 (6)
End-stage renal disease 5 (10) 12 (7) 2 (3)
Impaired creatinine clearance
(decreased by .25% of the LLN) or
abnormal protein:creatinine ratio
28 (58) 99 (54) 6 (10)
Proteinuria 33 (69) 132 (72) 20 (32)
Hematuria .11 or $10 RBCs/hpf
or red cell casts
29 (60) 132 (72) 19 (31)
Biopsy-proven glomerulonephritis 30 (94) of 32 101 (94) of 108 17 (27)
Pulmonary 21 (44)‡ 136 (74) 37 (60)
Chronic cough 11 (23)‡ 99 (54) 18 (29)
Wheeze or expiratory dyspnea 2 (4) 15 (8) 5 (8)
Alveolar hemorrhage/massive hemoptysis 7 (15)‡ 76 (42) 9 (15)
Pleurisy 4 (8) 25 (14) 3 (5)
Supplemental oxygen requirement 6 (13) 40 (22) 5 (8)
Respiratory failure 2 (4) 22 (12) 4 (6)
Imaging findings
Nodules 0 (0) 97 (54) 3 (4)
Fixed pulmonary infiltrates 0 (0) 64 (36) 4 (6)
Cavitations 0 (0) 38 (21) 3 (5)
Ear, nose, and throat 0 (0) 128 (70) 24 (39)
Septal perforation or nasal collapse 0 (0) 15 (8) 3 (5)
Recurrent nasal bloody
discharge/crusting/obstruction/ulcer
0 (0) 98 (53) 6 (10)
Chronic or recurrent sinusitis 0 (0) 71 (39) 5 (8)
Conductive or sensorineural hearing loss 0 (0) 19 (10) 3 (5)
Otitis/mastoiditis 0 (0) 31 (17) 5 (8)
Subglottic involvement 0 (0) 19 (10) 6 (10)
Oral ulcers/granulomata 2 (4) 27 (15) 3 (5)
Eyes 15 (31) 78 (43) 19 (31)
Conjunctivitis 3 (6) 21 (11) 3 (5)
Nonspecific red eye 1 (2) 19 (10) 6 (10)
Episcleritis 2 (4) 15 (8) 4 (6)
Proptosis or retroorbital mass 0 (0) 3 (2) 7 (11)
Retinal exudates, hemorrhages,
aneurysms, or vessel thrombosis
1 (2) 0 (0) 0 (0)
Cutaneous 25 (52) 86 (47) 20 (32)
Palpable purpura/petechial rash 15 (31) 49 (27) 8 (13)
Gastrointestinal 28 (58)§ 66 (36) 18 (29)
Nonspecific abdominal pain 18 (38)† 41 (22) 11 (18)
Chronic nausea 16 (33)‡ 22 (12) 7 (11)
Musculoskeletal 25 (52) 118 (65) 25 (40)
Arthralgia or confirmed arthritis 20 (42) 112 (61) 24 (39)
Myalgia, muscle weakness,
or confirmed myositis
9 (19) 24 (14) 4 (7)
Nervous system 10 (21) 36 (20) 15 (24)
Headache 6 (13) 20 (11) 9 (15)
Dizziness 2 (4) 12 (7) 5 (8)
Cardiovascular 3 (6) 10 (5) 2 (3)
Venous thrombosis 0 (0) 3 (2) 2 (3)
* Values are the number (%) of patients. ARChiVe5A Registry for Childhood Vasculitis: e-entry; MPA5
microscopic polyangiitis; AAV5 antineutrophil cytoplasmic antibody–associated vasculitis; LLN5 lower
limit of normal; RBCs5 red blood cells; hpf5 high-power field.
† P, 0.05 versus patients with granulomatosis with polyangiitis (Wegener’s) (GPA).
‡ P, 0.001 versus patients with GPA.
§ P, 0.01 versus patients with GPA.
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with these characteristic ENT features do not completely
fulfill the classification criteria for GPA, these so-called
surrogate markers of GPA, according to the EMA algo-
rithm, still relegate the patient to a diagnosis of GPA,
albeit the diagnosis may be considered to be incomplete.
These patients are therefore precluded from a diagnosis
of MPA; for the purposes of our study, these patients are
described as having unclassifiable AAV (Figure 1).
Among the 62 patients considered to have unclassifiable
AAV, 24 (39%) had upper airway (ENT) pathologic
features (Table 2).
Among the patients with GPA included in the
study, the most commonly reported upper airway abnor-
malities were chronic recurrent nasal symptoms (53%)
and recurrent or chronic sinusitis (39%) (Table 2). Oral
ulcers (15%), subglottic or tracheal stenosis/inflamma-
tion (10%), hearing loss (10%), and tissue damage from
septal perforations or nasal collapse (8%) occurred less
frequently than other upper airway manifestations.
Sinus imaging was performed on 123 patients with
GPA and 11 patients with MPA. There were no sinus
abnormalities identified among the patients with MPA.
Among the patients with GPA, the specifically character-
ized sinus abnormalities were abnormal fluid levels or
opacities (53%), bone destruction (6%), mass effect (5%),
and other unspecified abnormalities (31%). The results of
paranasal sinus imaging or upper airway biopsy performed
in 36 patients with GPA confirmed the presence of vascu-
litis in 8 patients (22%), were consistent with a diagnosis
of vasculitis in 13 patients (36%), and showed no evidence
of vasculitis in 15 patients (42%).
Other systems. Gastrointestinal symptoms were
significantly more frequent in patients with MPA (58%)
than in patients with GPA (36%). Chronic nausea was
specifically more frequent in patients with MPA (33% of
patients with MPA versus 12% of patients with GPA;
P, 0.04). Nonspecific abdominal pain was relatively com-
mon in both groups (38% of patients with MPA versus
22% of patients with GPA). Severe gastrointestinal
features of persistent diarrhea, bleeding, or ischemic
abdominal pain were each found in fewer than 5% of
patients in either group.
Skin involvement was reported in 48% of all
patients, and most frequently included palpable purpura
and/or petechial rash, in 31% of patients with MPA and
27% of patients with GPA. Other skin findings, found in
fewer than 10% of patients in either group, included sub-
cutaneous nodules (6% of patients with MPA versus 8%
of patients with GPA), infarctions (6% of patients with
MPA versus 3% of patients with GPA), livido (2% of
patients with MPA versus 1% of patients with GPA),
Raynaud’s phenomenon (0% of patients with MPA
versus 3% of patients with GPA), and subcutaneous
swelling (4% of patients with MPA versus 3% of patients
with GPA). Features of mucous membrane or eye involve-
ment, which were reported in 40% of all patients, included
red and/or painful eye conditions attributable to conjuncti-
vitis, episcleritis, or another nonspecific condition. Three
patients with GPA had proptosis with retroorbital mass,
and 1 patient with MPA had retinal exudates/hemorrhages/
aneurysms/vessel thrombosis. Relatively few patients with
either MPA (4%) or GPA (15%) presented with oral
ulcers.
A majority of patients in each group presented
with nonspecific musculoskeletal symptoms (52% of
patients with MPA and 65% of patients with GPA).
Among all patients, neurologic involvement was relatively
uncommon, with the more common features being
seizures (8% of patients with MPA and 3% of patients
with GPA) and the nonspecific symptoms of headache
(13% of patients with MPA and 11% of patients with
GPA) and dizziness (4% of patients with MPA and 7%
of patients with GPA). Severe neurologic features, such
as peripheral neuropathy, weakness, or stroke, were
reported in fewer than 3% of all patients. Cardiovascular
manifestations, primarily venous thromboses, were re-
corded in only 3 patients, all of whom had GPA.
Other laboratory features. The majority of all
patients presented with elevated markers of inflammation
and hematologic abnormalities. Marked elevation in the
erythrocyte sedimentation rate (.50 mm/hour) was typical
in both groups (65% of patients with MPA and 70% of
patients with GPA), while elevation in the levels of
C-reactive protein was more frequently observed in
patients with GPA (85%) than in those with MPA (65%;
P, 0.01). One-half of the patients with GPA had elevated
levels of both total white blood cells and neutrophils, com-
pared to one-third of the patients with MPA. Eosinophil
levels were normal in most patients. More than 80% of all
patients had anemia, and approximately one-third had ele-
vated platelet counts. Levels of the Von Willebrand anti-
gen (tested in only 10 patients with MPA and 59 patients
with GPA) were frequently elevated in both groups (60%
and 69% of patients, respectively). Increased antistreptoly-
sin O titers were observed more frequently among the
patients with MPA tested (39% of patients with MPA ver-
sus 13% of patients with GPA; P5 0.006). There was little
evidence of other infectious causes or concurrent diseases,
such as tuberculosis or hepatitis B or C.
MPO-ANCA and/or pANCA were more frequent
in patients with MPA (55%) than in those with GPA
(26%) (P, 0.01), whereas PR3-ANCA and/or cANCA
were more common in patients with GPA (67%) com-
pared to patients with MPA (17%; P, 0.01). In all, 26%
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of patients with MPA and 5% of patients with GPA
tested negative for ANCAs, whether tested by immuno-
fluorescence or by enzyme-linked immunosorbent assay.
Three patients did not undergo ANCA testing.
Initial therapies. The initial immunosuppressive
therapies administered to children with GPA and children
with MPA were very similar (Table 3). Nearly all of the
patients received corticosteroids (97%), and this was usu-
ally combined with another immunosuppressive drug.
Most patients (76%) were treated with cyclophosphamide
(69% of patients with MPA and 78% of patients with
GPA), while 11% received other conventional disease-
modifying antirheumatic drugs (DMARDs), which
included methotrexate, mycophenolate mofetil, or azathio-
prine (25% of patients with MPA and 13% of patients
with GPA), and 12% of patients were taking rituximab
(10% of patients with MPA and 13% of patients with
GPA), either singly or in combination with another
DMARD. In total, 6% of patients did not receive any of
the listed DMARDs or rituximab. Furthermore, 21% of
all patients received plasmapheresis. A significantly
smaller proportion of patients with MPA (21%) compared
to those with GPA (49%) received trimethoprim, either
for upper respiratory infection or Pneumocystis jiroveci
pneumonia prophylaxis (P5 0.0005). Antihypertensive
agents and/or angiotensin-converting enzyme inhibitors
were administered to 41% of all patients.
Patients with unclassifiable AAV. The 62
patients designated as having unclassifiable AAV were
predominantly female (76%). Among these patients, the
MD diagnosis was GPA (55%), MPA (13%), ANCA-
associated pauci-immune glomerulonephritis (6%), PAN
(5%), or unclassified AAV (21%). A majority of these
patients had constitutional features of disease (63%) and
pulmonary histopathologic features (60%). Other systems
involved, in decreasing frequency, were musculoskeletal
(40%), renal (39%), upper airways/ENT (39%), cutane-
ous (32%), and gastrointestinal (29%) (Table 2). The
results of testing for ANCAs, among the 59 patients with
unclassifiable AAV who were tested, were as follows: 36%
with PR3-ANCA and/or cANCA, 32% with MPO-ANCA
and/or pANCA, and 32% negative for ANCAs (details
available upon request from the corresponding author).
DISCUSSION
Our study involved the largest cohort of pediatric
patients with AAV described to date, albeit excluding
patients with EGPA. The relative ratio of patients with
GPA to patients with MPA from contributing centers
was 4:1, and this likely reflects a predominantly white
population of Northern European origin, in contrast to
previously studied populations from Japan and China
(22,23) and perhaps Southern Europe (24), where MPA
was more common than GPA. The subcohort of 183
patients with GPA in the current study is the largest
reported cohort of pediatric patients with that disease,
and includes 65 patients previously recruited to the
ARChiVe cohort up to November 2008 (5). The subcohort
of 48 pediatric patients with MPA is larger than the 5
largest previous pediatric case series that contained
retrospective data on patients with MPA from Turkey
Table 3. Initial treatments administered to the ARChiVe study participants classified as having MPA
or GPA*
Medication use
Patients with MPA
(n5 48)
Patients with GPA
(n5 183)
Corticosteroids 44 (92) 179 (98)
Corticosteroids plus cyclophosphamide 33 (69) 142 (78)
DMARDs collectively† 44 (92) 173 (95)
Cyclophosphamide (oral or IV) 33 (69) 142 (78)
Methotrexate (oral or subcutaneous) 4 (8) 20 (11)
Mycophenolate mofetil 4 (8) 2 (1)
Azathioprine 4 (8) 2 (1)
Rituximab 5 (10) 23 (13)
Intravenous immunoglobulin 2 (4) 10 (5)
Plasmapheresis 9 (19) 40 (22)
Trimethoprim sulfamethoxazole 10 (21)‡ 90 (49)
Other adjuvant medications 41 (85) 135 (74)
Antihypertensives with or without ACE inhibitors 26 (54)§ 68 (38)
* Values are the number (%) of patients. ARChiVe5A Registry for Childhood Vasculitis: e-entry; MPA5
microscopic polyangiitis; IV5 intravenous; ACE5 angiotensin-converting enzyme.
† Disease-modifying antirheumatic drugs (DMARDs) include cyclophosphamide, methotrexate,
mycophenolate mofetil, and azathioprine.
‡ P, 0.001 versus patients with granulomatosis with polyangiitis (Wegener’s) (GPA).
§ P, 0.05 versus patients with GPA.
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(n5 26), Japan (n5 21), Serbia (n5 7), Beijing, China
(n5 19), and Guangzhou, China (n5 16) (13–17). The
earliest of these studies, from Turkey (14), described 26
children with PAN, among whom 24 might now be con-
sidered to have MPA if diagnosed according to contem-
porary definitions. In the subsequent studies, patients
with MPA were distinguished from those with GPA
according to different disease definitions or descriptions
that have evolved over time. In the studies from Serbia
(15) and Beijing (17), the diagnosis of MPA, as distin-
guished from GPA, was ultimately determined by the
presence of MPO-ANCA or pANCA. In using the EMA
algorithm (10), the present study is the only one to define
patients as having MPA in a way that is mutually exclu-
sive of the diagnosis of GPA, EGPA, or PAN.
A variety of other criteria and definitions used by
pediatric rheumatologists for subclassifying patients as
having MPA or GPA were identified in an international
survey completed by a majority of physicians who con-
tributed patients to the ARChiVe cohort. These results,
describing a nonuniform approach to disease classifica-
tion, are provided in Patients and Methods as a rationale
for our decision to systematically reclassify our patient
cohort. Of note, among the 62 patients designated as hav-
ing unclassifiable AAV, the ratio of the assigned MD
diagnosis of GPA to that of MPA, a ratio of 4:1, was simi-
lar to that in the present study. Moreover, the predomi-
nance of female patients was similar to that in both the
GPA cohort and the MPA cohort. Generally, patients in
the cohort with unclassifiable AAV had more limited dis-
ease and had fewer systems involved, and therefore were
arguably less likely to fulfill the formal classification crite-
ria. The frequencies of patients with PR3-ANCA and/or
cANCA (36%), those with MPO-ANCA and/or pANCA
(32%), and those negative for ANCAs (32%) were
evenly distributed in patients with unclassifiable AAV,
and therefore the ANCA status was not indicative of this
group being more likely to have either GPA or MPA.
The discrepancy in frequency of patients formally
classified as having MPA according to the EMA algo-
rithm, when compared to those who were given an MD
diagnosis of MPA, was evaluated and discussed in depth
in our earlier study in which a smaller cohort of patients
recruited to the ARChiVe cohort was assessed (6).
Several patients who were classified formally as having
GPA were given the MD diagnosis of MPA, seemingly on
the basis of the type of ANCA (i.e., pANCA with specific-
ity for MPO).
The mean age at disease onset in patients with
MPA in our study (mean age 10.8 years) falls within the
range of ages (mean ages 9–12 years) from other pediatric
series (13–17). The marked predominance of female
patients in our study, a reported frequency of 73%, was
also characteristic of that in other case series, in which fre-
quencies of up to 90% have been described; only the
Turkish case series (14) had a lower frequency of female
patients, at 53%. This is in complete contrast to studies of
adult patients, in which a predominance of male patients
with MPA has been described, ranging from 55% to 60%
(12,25,26). Notably, the 2 more recent of these 3 studies
used an algorithmic classification of GPA (12,25).
The frequencies of involvement of different organ
systems (and specific presenting clinical features) in our
MPA cohort are listed in Table 2. The frequencies of the
more commonly involved systems fell within the wide range
of frequencies described in other pediatric case series
(13–17). The frequency of general constitutional symptoms
(85%) was in the low end of the ranges reported. Renal dis-
ease, present in 75% of the patients in the present study,
was also in the low end of the range of frequencies, and is in
contrast to that reported previously from Departments of
Nephrology, in which renal disease has been reported to be
present in 100% of patients (13–17). Skin manifestations,
predominantly palpable purpura or petechiae, occurred in
a majority of our patients (52%) and was consistent with
the reported frequencies (15–100%) in other studies (13–
17); it should be noted that the 100% frequency of skin
manifestations that was reported in the Serbian study was
observed in a cohort of only 7 patients.
In spite of the fact that the EMA algorithm char-
acteristically precludes a diagnosis of MPA among
patients with selected lung features on imaging, pulmo-
nary involvement, which was identified in a minority of
our patients (44%), was in the middle range of frequen-
cies that have been reported previously (15–62%)
(13–17). Gastrointestinal involvement occurred in a little
more than one-half of our patients, with nonspecific
abdominal pain and chronic nausea representing the pri-
mary manifestations and gastrointestinal bleeding occur-
ring in only 1 patient. Gastrointestinal involvement was
not typically characterized in other case series, but when
it was described, it occurred in 15–55% of patients
(4,13,15–17). Nervous system involvement was infre-
quent; notably, peripheral neuropathy was not reported,
a finding that was similar to that in other pediatric and
adult case series of patients in whom a diagnosis of PAN
was actively excluded (13,15–17).
The subcohort of 183 patients with GPA was triple
in size compared to the 2 previous largest pediatric case
series of 56 patients from the PRINTO database (27) and
65 patients from our earlier report on the ARChiVe cohort
(5). In the earlier ARChiVe report, patients were classified
as having GPA according to the ACR 1990 Criteria for
Vasculitis; however, since that time, pediatric-specific
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criteria have become available, and patients in both the
PRINTO study and in the present study were classified
according to the EULAR/PRINTO/PRES criteria (7).
Despite the difference in population pools and classifica-
tion criteria, the results of this much larger series overall
support the findings of the previous studies. The prepon-
derance of females and white patients was similar in all 3
studies. The median age at disease onset of 14 years
(median diagnostic delay of 2.1 months) in this study was
slightly older than that reported for patients in the
PRINTO registry, in which the median age at disease onset
was 11.7 years (median diagnostic delay of 4.2 months).
In comparing the current study with our earlier
report on the ARChiVe cohort, the frequencies of organ
system involvement among patients with GPA were very
similar, although among patients in the present study,
cutaneous findings were more frequent (47% versus
35%). Both venous thrombosis (3 patients) and periorbi-
tal masses (3 patients) were only observed among
patients in this later and larger cohort.
With regard to presenting clinical features, the fol-
lowing features were less frequent in the current ARChiVe
cohort than in patients from the PRINTO registry: ENT
findings (70% versus 91%), eye findings (12% versus
35%), and the presence of fixed lung infiltrates (36% versus
47%). In contrast, the following features were more fre-
quent in the ARChiVe cohort than in the PRINTO regis-
try: renal disease defined by hematuria and/or casts (72%
versus 63%), gastrointestinal findings (36% versus 16%),
the presence of hemoptysis/alveolar hemorrhage (42% ver-
sus 25%), and pulmonary nodules (54% versus 30%).
In spite of the slight variations in frequencies of
clinical features, our findings overall support the conclu-
sions of the PRINTO registry report, in that when com-
pared to the adult case series (using the same comparator
groups as used in that report [28–30]), adult patients
showed lower frequencies of constitutional, respiratory,
and renal involvement, and a higher frequency of conduc-
tive hearing loss. Unlike the PRINTO series, we did not
demonstrate a higher frequency of ENT findings in our
pediatric cohort when compared to adults. In contrast to
the findings in adult patients, so-called limited or localized
GPA, as defined by the absence of kidney disease,
occurred in a minority of children at diagnosis and at pre-
sentation. This apparent difference might reflect the
known difficulties in formally classifying children as having
GPA when they only have single-organ involvement (for
example, subglottic stenosis, chronic sinusitis, episcleritis,
or retroorbital mass) at presentation. Indeed, such
patients are more frequently designated as having unclas-
sifiable AAV (incomplete GPA), as was found in the
cohort of 62 patients in the present study, in whom the
time to diagnosis (diagnostic delay) was also longer than
that in either patients with GPA or patients with MPA.
In the absence of any formal classification criteria
for MPA, we have applied a modified pediatric EMA algo-
rithm and used categorical data provided by the contribut-
ing physicians to uniquely classify patients as having MPA
(i.e., without overlapping features of GPA). Using this
strategy, we were able to overcome the potentially differing
diagnostic/classification principles used by the variety of
pediatric rheumatologists at the 45 diverse institutions that
have contributed patients to ARChiVe.
While both GPA and MPA are included among
the spectrum of differential diagnoses for pulmonary/renal
syndromes, only a minority (44%) of patients with MPA
presented with any respiratory features. Patients with
GPA also tended to have more frequent and more severe
pulmonary manifestations (i.e., hemorrhage, requirement
for supplemental oxygen, or pulmonary failure) compared
to patients with MPA. In patients with MPA, the age at
disease onset was younger, and although the frequency of
renal disease was similar to that in patients with GPA, it
tended to be more severe in phenotype. Gastrointestinal
manifestations also occurred more frequently in patients
with MPA. Among the patients with GPA, however, 75%
presented with lower respiratory tract manifestations, and
the disease was associated with ANCAs directed against
the PR3 antigen. The presence of other surrogate markers
of GPA (including upper respiratory tract manifestations
of nasal and sinus involvement), as incorporated in the
EMA algorithm, precluded the diagnosis of MPA.
Similarly, the less frequent, but relatively specific, manifes-
tations of tracheal and subglottic stenosis or inflammatory
eye disease were found only in patients with GPA.
When comparing specific clinical manifestations in
patients with MPA and patients with GPA in our cohort,
features that were more prevalent among patients with
MPA included nephrotic-range proteinuria with edema,
renal failure requiring dialysis, and chronic nausea. While
we found that 75% of patients with MPA in our cohort
had renal disease, previous reports (predominantly from
Departments of Nephrology) have described renal mani-
festations in 100% of patients with MPA (13–17). The fre-
quency of nephrotic syndrome in our cohort (23%) was
similar to that in 2 case series from China (30%) (16) and
Serbia (29%) (15). A requirement for dialysis for renal
failure, around the time of diagnosis, was only described in
the Serbian study (15), and occurred in 29% of patients,
similar to the frequency of 25% in the present study.
Gastrointestinal involvement (specifically, chronic nausea)
was seen in one-half of the patients with MPA compared
to one-third of the patients with GPA, a finding that is
somewhat unique to our study; its relevance remains
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unclear. That being stated, it seems plausible that chronic
nausea, in particular, may also reflect more severe renal
disease in patients with MPA.
Prompt identification of AAV followed by initiation
of appropriate immunosuppressive treatment is crucial to
preventing adverse outcomes. Several studies of adult
patients have identified the level of kidney function at pre-
sentation and, in particular, whether dialysis is required, as
independent risk factors for mortality in patients with AAV
(31,32). We demonstrated wide variations in the time to
diagnosis. Thus, we speculate that variations in the rate of
onset and severity of prodromal symptoms may delay dis-
ease recognition in some patients. In addition, because of its
rarity, primary health care might not always consider AAV
among the diagnostic possibilities in pediatric patients.
Both MPA and GPA are rare, yet potentially devas-
tating, systemic vasculitides that affect the small and medium-
sized arteries in multiple organ systems. In the absence of
definitive diagnostic tests, classification criteria are an essen-
tial tool for characterizing and comparing patients with over-
lapping clinical phenotypes across studies. Although in this
comparative description of patients with MPA and patients
with GPA, the number of patients classified as having MPA
was relatively small, the findings are consistent with those in
previously described smaller cohorts. Nevertheless, our lim-
ited conclusions should be viewed with caution. Our study
has allowed us to delineate differences between MPA and
GPA, notably, an earlier age at disease onset and perhaps
more severe renal disease presentation in children with
MPA. The marked predominance of female patients in the
pediatric MPA cohort, compared to the predominance of
male patients in similarly classified adult cohorts, invokes a
cautionary note against making broad generalizations about
the similarities between adult and pediatric vasculitis.
International collaborations in childhood vasculi-
tis have led to the development and validation of classifi-
cation criteria for childhood vasculitis, have advanced our
understanding of the clinical phenotype at presentation
of childhood AAV, and have improved our ability to cap-
ture disease activity and determine treatment choices
(33). Ongoing biomarker-driven studies may complement
systems for subclassifying patients with AAV, and will
further shape our understanding of these diseases.
Several challenges remain with regard to evaluating the
safety and efficacy of current treatment strategies, which
have been largely derived from studies of adults, and
assessing the long-term morbidity in children with AAV.
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APPENDIX A: MEMBERS OF THE ARChiVe
INVESTIGATORS NETWORK
The coordinating center of the ARChiVe Investigators
Network was British Columbia Children’s Hospital (Vancouver, British
Columbia, Canada), with the following members: David A. Cabral
(Study Principal Investigator), Angelyne Sarmiento and Qun Yang
(Study Coordinators), Victor Espinosa (IT Manager), Joanna
Lubieniecki (Statistician), and Jaime Guzman, Kristin Houghton,
Kimberly Morishita, Ross Petty, and Lori Tucker (Site Investigators).
Other participating centers and members are as follows: Akron
Children’s Hospital (Akron, OH): Mary B. Toth (Site Principal
Investigator); Alberta Children’s Hospital (University of Calgary,
Calgary, Alberta, Canada): Susanne Benseler (Site Principal
Investigator), Marinka Twilt (Site Investigator); Alder Hey Children’s
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NHS Foundation Trust Hospital (Liverpool, UK): Michael Beresford
(Site Principal Investigator), Eileen Baildam (Site Co-Principal
Investigator); Ann & Robert H. Lurie Children’s Hospital of Chicago
(Chicago, IL): Marisa Klein-Gitelman (Site Principal Investigator),
Michael Miller and Megan Curran (Site Investigators); Birmingham
Children’s Hospital NHS Foundation Trust (Birmingham, UK):
Taunton Southwood (Site Principal Investigator); Breach Candy
Hospital (Mumbai, India): Raju Khubchandani (Site Principal
Investigator); Children’s Hospital at Montefiore (New York, NY):
Norman T. Ilowite (Site Principal Investigator), Dawn M. Wahezi (Site
Investigator); Children’s Hospital of Boston: Susan Kim (Site Principal
Investigator), Fatma Dedeoglu, Robert Fuhlbrigge, Melissa Hazen,
Mary Beth Son, and Robert Sundel (Site Investigators); Children’s
Hospital, Los Angeles (Los Angeles, CA): Andreas Reiff (Site Principal
Investigator), Diane Brown, Katherine Marzan, Anusha Ramanathan,
and Bracha Shaham (Site Investigators); Children’s Hospital of Eastern
Ontario (Ottawa, Ontario, Canada): Ciaran Duffy (Site Principal
Investigator); Children’s Hospital of Michigan (Detroit, MI): Matthew
Adams (Site Principal Investigator), Rudolf Valentini (Site
Investigator); Children’s Hospital of Pittsburgh (Pittsburgh, PA):
Margalit Rosenkranz (Site Principal Investigator), Daniel Kietz, Elaine
Cassidy, and Kathryn Torok (Site Investigators); Children’s Mercy
Hospital (Kansas City, MO): Mara Becker (Site Principal Investigator);
Children’s National Medical Center (Washington, DC): Lawrence K.
Jung (Site Principal Investigator); Cleveland Clinic Foundation
(Cleveland, OH): Steven Spalding (Site Principal Investigator), Andrew
Zeft (Site Investigator); Cohen Children’s Medical Center of New York
(New Hyde Park, NY): Anne Eberhard (Site Principal Investigator),
Bett Gottlieb and Cagri Toruner (Site Investigators); Comer Children’s
Hospital (Chicago, IL): Linda Wagner-Weiner (Site Principal
Investigator), Karen Onel, Charles Spencer, Deidre De Ranieri, and
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of New York—Presbyterian (New York, NY): Andrew Eichenfield (Site
Investigator), Lisa Imundo (Site Investigator); Duke Children’s Hospital
and Health Center (Duke University Medical Center, Durham, NC):
Heather Van Mater (Site Principal Investigator), C. Egla Rabinovich,
Laura Schanberg, and Jeffery Dvergsten (Site Investigators); Great
North Children’s Hospital (Newcastle, UK): Mark Friswell (Site
Principal Investigator); Hospital for Sick Children (Toronto, Ontario,
Canada): Rae Yeung (Site Principal Investigator), Brian Feldman,
Deborah Levy, Earl D. Silverman, Ronald Laxer, and Rayfel Schneider
(Site Investigators); Hospital Sant Joan de Deu Barcelona (Barcelona,
Spain): Jordi Anton (Site Principal Investigator); IWK Health Centre
and Dalhousie University (Halifax, Nova Scotia, Canada): Adam M.
Huber (Site Principal Investigator), Bianca A. Lang, Suzanne Ramsey,
and Elizabeth Stringer (Site Investigators); Janeway Children’s Health
and Rehabilitation Centre (St. John’s, Newfoundland, Canada): Paul
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Rochester, MN): Thomas Mason (Site Principal Investigator), Ann
Reed (Site Investigator); Medical College of Georgia (Augusta, GA):
Rita Jerath (Site Principal Investigator); Meyer Children’s Hospital
(Florence, Italy): Rolando Cimaz (Site Principal Investigator); Monroe
Carell Jr. Children’s Hospital at Vanderbilt (Nashville, TN): Thomas B.
Graham (Site Principal Investigator), Amy Woodward and Donna
Hummel (Site Investigators); Mother and Child Health Care Institute
of Serbia (Belgrade, Serbia): Goran Ristic (Site Principal Investigator);
Nationwide Children’s Hospital (Columbus, OH): Gloria C. Higgins
(Site Principal Investigator); Nuffield Orthopaedic Centre (University of
Oxford, Oxford, UK): Raashid Luqmani (Site Principal Investigator);
Phoenix Children’s Hospital (Phoenix, AZ): Kaleo Ede (Site Principal
Investigator), Michael Shishov (Site Investigator); Randall Children’s
Hospital at Legacy Emmanuel (Portland, OR): Daniel J. Kingsbury
(Site Principal Investigator), Victoria Cartwright and Andrew Lasky
(Site Investigators); Rigshospitalet (Copenhagen, Denmark): Susan
Nielsen (Site Principal Investigator); Riley Children’s Hospital
(Indianapolis, IN): Kathleen O’Neil (Site Principal Investigator), Peter
Chira, Susan Ballinger, Stacey Tarvin, and Michael Blakley (Site
Investigators); Royal Hospital for Children (Glasgow, UK): Neil Martin
(Site Principal Investigator); Royal Manchester Children’s Hospital
(Manchester, UK): Janet McDonagh (Site Principal Investigator);
Rutgers-Robert Wood Johnson Medical School (New Brunswick, NJ):
Lakshmi Nandini Moorthy (Site Principal Investigator), Alexis
Boneparth (Site Investigator); Saint Louis Children’s Hospital
(Washington University School of Medicine, St. Louis, MO): Kevin
Baszis (Site Principal Investigator), Andrew White (Site Investigator);
Saint-Petersburg State Pediatric Medical University (St. Petersburg,
Russia): Mikhail Kostik (Site Principal Investigator); Seattle Children’s
Hospital (Seattle, WA): Susan Shenoi (Site Principal Investigator),
Kabita Nanda, Anne Stevens, Alexandra Aminoff, and Carol Wallace
(Site Investigators); Sheffield Children’s NHS Foundation Trust
(Sheffield, UK): Anne-Marie McMahon (Site Principal Investigator);
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(Stanford University School of Medicine, Stanford, CA): Tzielan Lee
(Site Principal Investigator), Imelda Balboni, Michal Cidon, Jennifer
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Hospital (Baylor College of Medicine, Houston, TX): Eyal Muscal (Site
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Montreal Children’s Hospital (McGill University Health Centre,
Montreal, Quebec, Canada): Sarah Campillo (Site Principal
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Thomas Lehman (Site Principal Investigator), Laura Barinstein, Emma
MacDermott, and Alexa Adams (Site Investigators); University
Children’s Hospital Muenster (Muenster, Germany): Dirk Foel (Site
Principal Investigator); University Hospitals Case Medical Center
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